This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

A multicenter, open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in Binswanger-type subcortical vascular dementia


Jay Cheol Kwon,, Eung Gyu Kim,, Jae Woo Kim,, Oh Dae Kwon,, Bong Goo Yoo,, Hyon Ah Yi,, Nack Cheon Choi,, Seon Young Ahn,, Byung Hwa Lee,, Myong Jin Kang,, Dae Seob Choi,


American Journal Of Alzheimer's Disease And Other Dementias, Volume: 24, No.: 4, Pages.: 293-301

Year of Publication



Objectives: To evaluate the efficacy and tolerability of donepezil in patients with Binswanger type subcortical vascular dementia.; Methods: Patients (n = 34, mean age = 71.8 + 7.12) with Binswanger type subcortical vascular dementia from 8 multicenter, according to clinical and neuroradiological working criteria, were selected to receive donepezil 5 mg/day (n = 2) or donepezil 10 mg/day (n = 32, after 5 mg/day) for 24 weeks. Our primary endpoints were change from baseline to weeks 12 and 24 in the Seoul Neuropsychological Screening Battery-Dementia version (SNSB-D) and the Korean version of neuropsychiatric inventory (K-NPI).; Results: A total of 24 patients received donepezil completed the study (mean age = 72.0 + 7.5 K-Mini-Mental State Examination [MMSE] = 21.0 + 5.1). After 12 weeks and 24 weeks, patients showed improvements in cognitive function on the SNSB-D compared baseline of 16.29 points at 12 weeks (P < .05) and 12.44 points at 24 weeks (P < .05). Significant improvements were shown in only memory domain, immediate verbal recall and delayed recall tests. Subgroup with better cognitive function (SNSB-D > 100) were more effective in frontal and memory domains than the other subgroup (SNSB-D < 100). Withdrawal rates due to adverse events were very low (4.16%).; Conclusions: Donepezil-treated patients with Binswanger type subcortical vascular dementia demonstrated significant improvement in cognition compared with baseline, and donepezil was well tolerated.;

Bibtex Citation

@article{Jay_Cheol_Kwon_2009, doi = {10.1177/1533317509334960}, url = {}, year = 2009, month = {apr}, publisher = {{SAGE} Publications}, volume = {24}, number = {4}, pages = {293--301}, author = {Jay Cheol Kwon and Eung Gyu Kim and Jae Woo Kim and Oh Dae Kwon and Bong Goo Yoo and Hyon Ah Yi and Nack Cheon Choi and Seon Young Ahn and Byung Hwa Lee and Myong Jin Kang and Dae Seob Choi}, title = {A Multicenter, Open-Label, 24-Week Follow-Up Study for Efficacy on Cognitive Function of Donepezil in Binswanger-Type Subcortical Vascular Dementia}, journal = {American Journal of Alzheimer{textquotesingle}s Disease and Other Dementias} }


administration & dosage, adverse effects, aged, aged, 80 and over, cognition, cognition disorders, dementia vascular, donezepil, drug effects, drug therapy, female, humans, indans, magnetic resonance imaging, male, middle aged, nootropic agents, pathology, piperidines, treatment outcome

Types of Dementia

Vascular Dementia

Types of Study

Before and After Study

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime